Tactics for vascular protection after acute ischemic stroke

Pharmacotherapy

Volumn 25, Issue 3, 2005, Pages 387-395

  Fagan, Susan C ^a,b,c   Hess, David C ^b,c   Machado, Livia S ^a,c   Hohnadel, Elizabeth J ^a   Pollock, David M ^b   Ergul, Adviye ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute ischemic stroke; Molecular processes; Vascular protection

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN ANTAGONIST; BASIC FIBROBLAST GROWTH FACTOR; CASPASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ERYTHROPOIETIN; GELATINASE A; GELATINASE B; GENE PRODUCT; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 1; MINOCYCLINE; NITRIC OXIDE; PROTEIN BAX; PROTEIN BCL 2; STATIN; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

BLOOD VESSEL INJURY; BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN PROTECTION; CARDIOVASCULAR RISK; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MEDIATOR RELEASE; NEUROPROTECTION; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOPHYSIOLOGY; REVIEW; STROKE; TREATMENT FAILURE;

ACUTE DISEASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRAIN; BRAIN EDEMA; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; ERYTHROPOIETIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MINOCYCLINE; THIAZOLIDINEDIONES; THROMBOLYTIC THERAPY;

EID: 14544276825     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.3.387.61592     Document Type: Review

References (78)

1. Lammert E, Cleaver O, Melton D. Induction of pancreatic differentiation by signals from blood vessels. Science 2001;294:564-7.
2. Matsumoto K, Yoshitomi H, Rossant J, Zaret KS. Liver organogenesis promoted by endothelial cells prior to vascular function. Science 2001;294:559-63.
3. Cipolla MJ, McCall AL, Lessov N, Porter JM, Kontos H. Reperfusion decreases myogenic reactivity and alters middle cerebral artery function after focal cerebral ischemia in rats. Stroke 1997;28:176-80.
4. Faraci FM. Vascular protection. Stroke 2003;34:327-9.
5. Fagan SC, Hess DC, Hohnadel EJ, Pollock DM, Ergul A. Targets for vascular protection after ischemic stroke. Stroke 2004;35:2220-5.
6. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
7. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998;29:4-11.
8. Sherman DG, Atkinson RP, Chippendale T, et al, for the STAT Participants. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study - a randomized controlled trial. JAMA 2000;283:2395-403.
9. Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in acute ischemic stroke trials through the 20th century. Stroke 2001;32:1349-59.
10. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002;33:2123-36.
11. Jonas S, Aiyagari V, Vieira D, Figueroa M. The failure of neuronal protective agents versus the success of thrombolysis in the treatment of ischemic stroke: the predictive value of animal models. Ann N Y Acad Sci 2001;939:257-67.
12. Hayashi T, Noshita N, Sugawara T, Chan PH. Temporal profile of angiogenesis and expression of related genes in the brain after ischemia. J Cereb Blood Flow Metab 2003;23:166-80.
13. George SJ. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin Investig Drugs 2000;9:993-1007.
14. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 1995;26:2120-6.
15. del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry 1998;65:1-9.
16. Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002;33:2711-17.
17. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003;34:2165-70.
18. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002;33:831-6.
19. Wang CX, Yang T, Shuaib A. Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Brain Res 2003;963:327-9.
20. Bowes MP, Zivin JA, Thomas GR, Thibodeaux H, Pagan SC. Acute hypertension, but not thrombolysis, increases the incidence and severity of hemorrhagic transformation following experimental stroke in rabbits. Exp Neurol 1996;141:40-6.
21. Fagan SC, Bowes MP, Lyden PD, Zivin JA. Acute hypertension promotes hemorrhagic transformation in a rabbit embolic stroke model: effect of labetalol. Exp Neurol 1998;150:153-8.
22. Levy DE, Brott TG, Haley EC Jr, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994;25:291-7.
23. Gilligan AK, Markus R, Read S, et al. Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke 2002;33:2236-42.
24. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000;31:3034-40.
25. Lapchak PA, Araujo DM, Song D, Zivin JA. The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke. Stroke 2002;33:147-52.
26. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino) methyl] benzene-1,3- disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 2002;33:1411-15.
27. Steiner T, Ringleb P, Hacke W. Treatment options for large hemispheric stroke. Neurology 2001;57:S61-8.
28. Faggiotto A, Paoletti R. State-of-the-art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension 1999;34:987-96.
29. Ferro A. Statins and vascular protection: a 'radical' view. J Hypertens 2002;20:359-61.
30. Dogra GK, Watts GF, Herrmann S, Thomas MA, Irish AB. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int 2002;62:550-7.
31. Nakamura K, Al-Ruzzeh S, Chester AH, et al. Effects of cerivastatin on vascular function of human radial and left internal thoracic arteries. Ann Thorac Surg 2002;73:1860-5.
32. Weis M, Pehlivanli S, Meiser BM, von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001;38:814-8.
33. Marchesi S, Lupattelli G, Siepi D, et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 2000;36:617-21.
34. Rosenson RS. Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999;1:225-32.
35. Wheeler DC. Are there potential non-lipid-lowering uses of statins? Drugs 1998;56:517-22.
36. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002;86:5-18.
37. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. P13K/Akt and apoptosis: size matters. Oncogene 2003;22:8983-98.
38. Paez J, Sellers WR. P13K/PTEN/Akt pathway: a critical mediator of oncogenic signaling. Cancer Treat Res 2003;115:145-67.
39. Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53:743-51.
40. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-5.
41. Gertz K, Laufs U, Lindauer U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003;34:551-7.
42. Amin-Hanjani S, Stagliano NE, Yamada M, et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice [editorial]. Stroke 2001;32:980-6.
43. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001;89:866-73.
44. Ruschitzka F, Noll G, Luscher TF. Angiotensin-converting enzyme inhibitors and vascular protection in hypertension. J Cardiovasc Pharmacol 1999;34(suppl 1):S3-12.
45. Berry C, Hamilton CA, Brosnan MJ, et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000;101:2206-12.
46. Berry C, Brosnan MJ, Fennell J, Hamilton CA, Dominiczak AF. Oxidative stress and vascular damage in hypertension. Curr Opin Nephrol Hypertens 2001;10:247-55.
47. Didion SP, Faraci FM. Angiotensin II produces superoxide-mediated impairment of endothelial function in cerebral arterioles. Stroke 2003;34:2038-42.
48. Brosnan MJ, Hamilton CA, Graham D, Lygate CA, Jardine E, Dominiczak AF. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens 2002;20:281-6.
49. Moreau P, d'Uscio L, Shaw S, Takase H, Barton M, Luscher T. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997;96:1593-7.
50. Cerami A, Brines M, Ghezzi P, Cerami C, Itri LM. Neuroprotective properties of epoetin alfa. Nephrol Dial Transplant 2002;17:8-12.
51. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κ B signalling cascades. Nature 2001;412:641-7.
52. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-31.
53. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotoxic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 2001;276:39469-75.
54. Genc S, Akhisaroglu M, Kuralay F, Gene K. Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine- induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neurosci Lett 2002;321:73-6.
55. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
56. Springborg JB, Ma X, Rochat P, et al. A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats. Br J Pharmacol 2002;135:823-9.
57. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002;106:2973-9.
58. Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab 2003;23:320-30.
59. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003;60:1234-40.
60. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999;96:13496-500.
61. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 2001;166:7527-33.
62. He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 2001;909:187-93.
63. Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002;22:1763-71.
64. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 2001;48:1393-401.
65. Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM, Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett 2001;315:61-4.
66. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-8.
67. Sasamura H, Takahashi A, Miyao N, et al. Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer 2002;86:768-73.
68. Imamura T, Matsushita K, Travis J, Potempa J. Inhibition of trypsin-like cysteine proteinases (Gingipains) from Porphyromonas gingivalis by tetracycline and its analogues. Antimicrob Agents Chemother 2001;45:2871-6.
69. Golub LM, Sorsa T, Lee HM, et al. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol 1995;22:100-9.
70. Sadowski T, Steinmeyer J. Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as of their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1. Inflamm Res 2001;50:175-82.
71. Power C, Henry S, Del Bigio MR, et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 2003;53:731-42.
72. Martens FM, Visseren FL, Lemay J, deKoning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-80.
73. Tao L, Liu HR, Gao E, et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-γ agonist in hypercholesterolemia. Circulation 2003;108:2805-11.
74. Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation 2002;105:2296-302.
75. Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPAR-γ: differentiation-dependent PPAR-γ expression and reduction of MMP-9 activity through PPAR-γ activation in mononuclear phagocytes in vitro. Am J Pathol 1998;153:17-23.
76. Ricote M, Li AC, Willson TM, et al. The PPAR-γ is a negative regulator of macrophage activation. Nature 1998;391:79-82.
77. Delerive P, Martin-Nizard F, Chinetti G, et al. PPARs inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999;85:394-402.
78. Kernan WN, Inzucchi SE, Viscoli CM, et al. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 2003;34:1431-6.